−50% from the high · +2.8% from the low
No listed options on MLTX
Profit −$61.8M in the Jun 2026 quarter, consolidated.
| Quarter | Revenue $ | Revenue YoY | Profit $ | Profit YoY | EPS $ | Market on the day |
|---|---|---|---|---|---|---|
| Jun 2026filed Aug 10 | — | — | −$61.8M | — | -0.84 | ▼ −4.3%S&P 500 −0.3% · −4.0 pp |
| Mar 2026filed May 11 | — | — | −$69.7M | — | -0.98 | ▼ −3.5%S&P 500 −0.2% · −3.3 pp |
| Dec 2025filed Feb 25 | — | — | −$62.4M | — | -0.93 | —not reached |
| Sep 2025filed Nov 5 | — | — | −$69.7M | — | -1.10 | —not reached |
| Jun 2025filed Aug 10 | — | — | −$55.2M | — | -0.87 | ▼ −4.3%S&P 500 −0.3% · −4.0 pp |
| Mar 2025filed May 11 | — | — | −$39.9M | — | -0.63 | ▼ −3.5%S&P 500 −0.2% · −3.3 pp |
| Dec 2024filed Feb 26 | — | — | −$45.6M | — | -0.72 | —not reached |
| Sep 2024filed Nov 5 | — | — | −$35.4M | — | -0.56 | —not reached |
| Year | Revenue $ | Revenue YoY | Profit $ | Profit YoY | EPS $ |
|---|---|---|---|---|---|
| FY25to Dec 2025 | — | — | −$227.3M | — | -3.53 |
| FY24to Dec 2024 | — | — | −$118.9M | — | -1.89 |
| FY23to Dec 2023 | — | — | −$36.0M | — | -0.73 |
| FY22to Dec 2022 | — | — | −$50.0M | — | -1.70 |
| FY21to Dec 2021 | — | — | −$4.5M | — | — |
2.3 times book value, market cap $995.7M.
| Stock | Market cap | P/E | P/B | Close $ |
|---|---|---|---|---|
| REGNRegeneron Pharmaceuticals Inc | $71.24Bon Sep 30 | 19consolidated | 2.3 | $758.27 |
| UTHRUnited Therapeutics Corp | $23.24Bon Sep 30 | 19consolidated | 3.6 | $541.89 |
| RPRXRoyalty Pharma plc Class A Ordinary Shares | $22.65Bon Sep 30 | 31consolidated | — | $58.36 |
| BMRNBioMarin Pharmaceuticals Inc | $11.61Bon Sep 30 | 150consolidated | 1.8 | $60.00 |
| LQDALiquidia Corporation Common Stock | $2.71Bon Sep 30 | 22consolidated | 14 | $30.26 |
| ANIPANI Pharmaceuticals, Inc. | $1.77Bon Sep 30 | 16consolidated | 3.0 | $72.65 |
| STOKStoke Therapeutics, Inc. Common Stock | $1.68Bon Sep 30 | — | 4.9 | $26.00 |
| MLTXMoonLake Immunotherapeutics Class A Ordinary Shares | $995.7Mon Sep 30 | — | 2.3 | $11.70 |
| JBIOJade Biosciences, Inc. Common Stock | $893.5Mon Sep 30 | 1.7consolidated | 2.0 | $14.05 |
| CLYMClimb Bio, Inc. Common Stock | $658.8Mon Sep 30 | — | 2.8 | $11.47 |
13F managers hold 160% of shares, BVF INC/IL the largest at 38%, Deep Track Capital, LP 16% and D. E. Shaw & Co., Inc. 7.9%, as filed for the quarter to Jun 2026.
| Manager | Shares | Of outstanding | Value | Change on quarter |
|---|---|---|---|---|
| BVF INC/IL | 32M | 38% | $623.1M | unchanged |
| Deep Track Capital, LP | 14M | 16% | $272.5M | +1.18M |
| D. E. Shaw & Co., Inc. | 6.73M | 7.9% | $131.1M | +1.95M |
| Cormorant Asset Management, LP | 6.41M | 7.5% | $124.8M | −2.55M |
| Jupiter Topco LLC | 6.17M | 7.3% | $120.2M | — |
| Logos Global Management LP | 5.35M | 6.3% | $104.2M | +2.35M |
| Weiss Asset Management LP | 5.16M | 6.1% | $100.5M | +1.75M |
| CITADEL ADVISORS LLC | 3.95M | 4.6% | $76.8M | +1.3M |
| TWO SIGMA INVESTMENTS, LP | 3.43M | 4.0% | $66.8M | +1.19M |
| MPM BIOIMPACT LLC | 3.21M | 3.8% | $62.6M | −408K |
No open-market insider buying or selling in the last 90 days.
| Insider | Trade | Shares | Price | Held after |
|---|---|---|---|---|
| Bodenstedt MatthiasOfficer | sold · Jun 22, 2026 | 39,120 | $22.04 | 1,115,435 |
| Bodenstedt MatthiasOfficer | sold · Jun 18, 2026 | 2,794 | $19.60 | 1,154,555 |
| Bodenstedt MatthiasOfficer | sold · Jun 17, 2026 | 15,082 | $19.68 | 1,157,349 |
| Reich KristianOfficer | sold · Jun 17, 2026 | 50,000 | $19.43 | 2,824,551 |
| Reich KristianOfficer | sold · Jun 16, 2026 | 50,000 | $18.70 | 2,874,551 |
| Reich KristianOfficer | sold · Jun 15, 2026 | 50,000 | $18.89 | 2,924,551 |
| Bodenstedt MatthiasOfficer | sold · May 11, 2026 | 13,653 | $20.02 | 1,172,431 |
| Bodenstedt MatthiasOfficer | sold · Apr 14, 2026 | 2,426 | $19.56 | 1,186,084 |
| Santos da Silva JorgeDirector,Officer | sold · Apr 10, 2026 | 98,127 | $18.41 | 2,976,766 |
| Santos da Silva JorgeDirector,Officer | sold · Apr 13, 2026 | 51,873 | $18.23 | 2,924,893 |
No corporate action on record for MLTX yet.
MLTX is −22.7% over 20 sessions against the S&P 500's +0.1%, 50% below its 52-week high, realised volatility 55% annualised.
| Window | From $ | MLTX % | S&P 500 % | Difference pp |
|---|---|---|---|---|
| 120 sessionssince Apr 9 | $19.41 | ▼ −40% | ▲ +12% | −52 |
| 60 sessionssince Jul 7 | $19.15 | ▼ −39% | ▲ +2.0% | −41 |
| 20 sessionssince Sep 1 | $15.13 | ▼ −23% | ▲ +0.11% | −23 |
| 5 sessionssince Sep 23 | $12.90 | ▼ −9.3% | ▼ −0.67% | −8.6 |
| 1 sessionsince Sep 29 | $11.45 | ▲ +2.2% | ▼ −0.21% | +2.4 |
Short sales were 47% of reported volume on Sep 30, 2026, against 34% over the last 25 sessions.
| Session | Short volume | Reported volume | Short share |
|---|---|---|---|
| Sep 30, 2026 | 293K | 623K | 47.1% |
| Sep 29, 2026 | 270K | 640K | 42.1% |
| Sep 28, 2026 | 194K | 599K | 32.4% |
| Sep 25, 2026 | 431K | 928K | 46.4% |
| Sep 24, 2026 | 386K | 920K | 42.0% |
| Sep 23, 2026 | 471K | 1.06M | 44.5% |
| Sep 22, 2026 | 161K | 1.01M | 16.0% |
| Sep 21, 2026 | 112K | 591K | 19.0% |
| Sep 18, 2026 | 150K | 772K | 19.4% |
| Sep 17, 2026 | 146K | 859K | 17.0% |
| Filed | Form | Report date |
|---|---|---|
| Sep 30, 2026 | 8-K | Sep 30, 2026 |
| Aug 14, 2026 | SCHEDULE 13G | — |
| Aug 14, 2026 | SCHEDULE 13G/A | — |
| Aug 14, 2026 | SCHEDULE 13G/A | — |
| Aug 10, 2026 | 10-Q | Jun 30, 2026 |
| Aug 10, 2026 | S-8 | — |
| Aug 10, 2026 | S-3ASR | — |
| Aug 10, 2026 | 8-K | Aug 10, 2026 |
| Jul 29, 2026 | 4 | Jul 27, 2026 |
| Jul 23, 2026 | 4 | Jul 21, 2026 |
| Jul 21, 2026 | 4 | Jul 20, 2026 |
| Jul 20, 2026 | 4 | Jul 15, 2026 |
| Jul 15, 2026 | 144 | — |
| Jul 15, 2026 | 8-K | Jul 14, 2026 |
| Jul 13, 2026 | 4 | Jul 9, 2026 |
| Jul 2, 2026 | 4 | Jul 1, 2026 |
| Jun 30, 2026 | 144 | — |
| Jun 29, 2026 | SCHEDULE 13D/A | — |
| Jun 25, 2026 | 8-K | Jun 23, 2026 |
| Jun 24, 2026 | 424B5 | — |
| Jun 23, 2026 | 4 | Jun 22, 2026 |
| Jun 22, 2026 | 424B5 | — |
| Jun 22, 2026 | 8-K | Jun 21, 2026 |
| Jun 22, 2026 | 4 | Jun 17, 2026 |
| Jun 18, 2026 | 4 | Jun 17, 2026 |
OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.